Literature DB >> 7190532

A comparison of the antiemetic effects of droperidol and prochlorperazine in chemotheray with cis-platinum.

A J Jacobs, G Deppe, C J Cohen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7190532     DOI: 10.1016/0090-8258(80)90063-3

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  8 in total

Review 1.  Myths and realities of antiemetic treatment.

Authors:  M Martin
Journal:  Br J Cancer Suppl       Date:  1992-12

Review 2.  Droperidol for treatment of nausea and vomiting in palliative care patients.

Authors:  Jemma Storrar; Morwenna Hitchens; Tracey Platt; Saskie Dorman
Journal:  Cochrane Database Syst Rev       Date:  2014-11-27

Review 3.  Pharmacological Agents Affecting Emesis : A Review (Part II).

Authors:  F Mitchelson
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

Review 4.  Intestinal and liver toxicity of antineoplastic drugs.

Authors:  G B McDonald; N Tirumali
Journal:  West J Med       Date:  1984-02

5.  The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis.

Authors:  G Wampler
Journal:  Drugs       Date:  1983-02       Impact factor: 9.546

6.  Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis.

Authors:  T C Chang; F Hsieh; C H Lai; C J Tseng; H H Cheng; C L Li; B J Michael; Y K Soong
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

7.  Oral levonantradol in the control of cancer chemotherapy-induced emesis.

Authors:  J Welsh; F Stuart; G Sangster; R Milstead; S Kaye; H Cash; D Charlton; K Calman
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

8.  Chlorpromazine, placebo and droperidol in the treatment of nausea and vomiting associated with cisplatin therapy.

Authors:  R Stuart-Harris; R Buckman; I Starke; E Wiltshaw
Journal:  Postgrad Med J       Date:  1983-08       Impact factor: 2.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.